This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

II. Calcitriol, 1-Hydroxyvitamin D3, and 24,25-Dihydroxyvitamin D3

Anne L. Voigts, MD; Arnold J. Felsenfeld, MD; Francisco Llach, MD

Arch Intern Med. 1983;143(6):1205-1211.

Abstract
• The available data with regard to the use of calcitriol, 1-hydroxyvitamin D₃ (1-OH D₃), and 24,25-dihydroxyvitamin D₃ (24,25-[OH]₂D₃) in the management of chronic renal insufficiency are reviewed. Patients with mild to moderate osteitis fibrosa experience substantial improvement with either calcitriol or 1-OH D₃ therapy. However, few patients experience a reversal to normal in histologic characteristics of bone. The conditions of patients with osteomalacia do not respond to either calcitriol or 1-OH D₃ therapy. The bone lesion appearing in these patients is most likely a toxic effect of aluminum. The prognosis is usually poor, but the conditions of some patients may respond to administration of 24,25-(OH)₂D₃ together with calcitriol. Preliminary data suggest that use of chelating agents may be beneficial. In this group of patients, 24,25-(OH)₂D₃ administration together with calcitriol may be beneficial.

(Arch Intern Med 1983;143:1205-1211)

Author Affiliations
From the Nephrology Section, Department of Medicine, University of Oklahoma Health Sciences Center, and the Veterans Administration Medical Center, Oklahoma City.

Footnotes
Accepted for publication Oct 21, 1982.

Reprint requests to Nephrology Section (111G), VA Medical Center, 921 NE 13th St, Oklahoma City, OK 73104 (Dr Llach).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?